T 0295/22 (Orally administered apremilast/AMGEN) of 20.11.2024
- European Case Law Identifier
- ECLI:EP:BA:2024:T029522.20241120
- Date of decision
- 20 November 2024
- Case number
- T 0295/22
- Petition for review of
- -
- Application number
- 15177140.9
- Language of proceedings
- English
- Distribution
- Distributed to board chairmen (C)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- Abstract on Article 054 EPC
- Application title
- (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF
- Applicant name
- Amgen (Europe) GmbH
- Opponent name
- Teva Pharmaceutical Industries Ltd.
Hoffmann Eitle Patent- und Rechtsanwälte
Partnerschaftsgesellschaft mbB
Accord Healthcare Ltd
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.
Generics (UK) Ltd
Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi
Hexal AG
Química Sintética, S.A.
Cipla Ltd
Zentiva k.s.
KRKA, d.d., Novo mesto
Dr. Reddy's Laboratories Limited
Alfred E. Tiefenbacher (GmbH & Co. KG)
STADA Arzneimittel AG
Galenicum Health S.L.U. - Board
- 3.3.07
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 123(2)European Patent Convention Art 56Guidelines_G-VI 6.1(2)Rules of procedure of the Boards of Appeal 2020 Art 012(4)Rules of procedure of the Boards of Appeal 2020 Art 013(2)
- Keywords
- Amendments - main request
Amendments - allowable (no)
Inventive step - auxiliary request (no)
Amendment to case - amendment within meaning of Art. 12(4) RPBA 2020
Amendment to case - allowable (yes)
Amendment after notification of Art. 15(1) RPBA communication - auxiliary request
Amendment after notification of Art. 15(1) RPBA communication - exceptional circumstances (yes)
Amendment after notification of Art. 15(1) RPBA communication - additional auxiliary request
Amendment after notification of Art. 15(1) RPBA communication - exceptional circumstances (no) - Catchword
- The requirement underlying the specificity of the use within the meaning of Article 54(5) of the EPC 2000 is according to the explicit conclusion in G 2/08 (see reasons 5.10.3) to be construed merely by contrast to the generic broad protection conferred by the first claimed medical application of a substance or composition, and is in principle not confined to a particular medical indication (see reasons 4.1).
- Cited cases
- G 0005/83G 0002/08T 0051/93T 0970/00T 0230/01T 1287/14T 0072/18T 1126/19T 1356/21T 1654/22
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is revoked.